Literature DB >> 16645165

Fondaparinux is a safe alternative in case of heparin intolerance during pregnancy.

Lucia Mazzolai1, Patrick Hohlfeld, Francois Spertini, Daniel Hayoz, Marc Schapira, Michel A Duchosal.   

Abstract

Heparin is the drug of choice for the treatment or the prevention of thromboembolic disease during pregnancy. However, treatment options are limited when heparin cannot be used because of hypersensitivity skin reactions. Despite the recent availability of new anticoagulant agents, data relating to their use during pregnancy are lacking. This report describes the successful management with fondaparinux, during 150 days, of a pregnant patient with protein S deficiency and prior deep vein thrombosis (DVT) who developed heparin and danaparoid hypersensitivity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16645165     DOI: 10.1182/blood-2006-03-009548

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Shannon M Bates; Ian A Greer; Saskia Middeldorp; David L Veenstra; Anne-Marie Prabulos; Per Olav Vandvik
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Lori-Ann Linkins; Antonio L Dans; Lisa K Moores; Robert Bona; Bruce L Davidson; Sam Schulman; Mark Crowther
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

3.  A systematic review on the use of new anticoagulants in pregnancy.

Authors:  Ai-Wei Tang; Ian Greer
Journal:  Obstet Med       Date:  2013-05-03

4.  Heparin induced thrombocytopenia: position paper from the Italian Society on Thrombosis and Haemostasis (SISET).

Authors:  Rossella Marcucci; Martina Berteotti; Anna M Gori; Betti Giusti; Angela A Rogolino; Elena Sticchi; Agatina Alessandrello Liotta; Walter Ageno; Erica De Candia; Paolo Gresele; Marina Marchetti; Marco Marietta; Armando Tripodi
Journal:  Blood Transfus       Date:  2020-12-28       Impact factor: 3.443

Review 5.  Deep venous thrombosis in pregnancy: incidence, pathogenesis and endovascular management.

Authors:  Paola Devis; M Grace Knuttinen
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

Review 6.  Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician.

Authors:  Connie N Hess; Richard C Becker; John H Alexander; Renato D Lopes
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

7.  Incidence and causes of heparin-induced skin lesions.

Authors:  Marc Schindewolf; Svantje Schwaner; Manfred Wolter; Hartmut Kroll; Andreas Recke; Roland Kaufmann; Wolf-Henning Boehncke; Edelgard Lindhoff-Last; Ralf J Ludwig
Journal:  CMAJ       Date:  2009-09-28       Impact factor: 8.262

8.  Use of fondaparinux in a pregnant woman with pulmonary embolism and heparin-induced thrombocytopenia.

Authors:  Michał Ciurzyński; Krzysztof Jankowski; Bronisława Pietrzak; Natalia Mazanowska; Ewa Rzewuska; Robert Kowalik; Piotr Pruszczyk
Journal:  Med Sci Monit       Date:  2011-05

9.  Guidance for the treatment and prevention of obstetric-associated venous thromboembolism.

Authors:  Shannon M Bates; Saskia Middeldorp; Marc Rodger; Andra H James; Ian Greer
Journal:  J Thromb Thrombolysis       Date:  2016-01       Impact factor: 2.300

10.  Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Pregnancy in pulmonary hypertension.

Authors:  Javed Khan; Majdy M Idrees
Journal:  Ann Thorac Med       Date:  2014-07       Impact factor: 2.219

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.